BRIEF published on 04/23/2026 at 15:15, 2 months 1 day ago Newron Pharmaceuticals annonce les résultats de son assemblée générale annuelle 2026 Newron Pharmaceuticals Evenamide Membres Du Conseil D'administration Assemblée Générale Annuelle 2026 Xadago®
BRIEF published on 04/23/2026 at 15:15, 2 months 1 day ago Newron Pharmaceuticals Announces AGM 2026 Results Board Members Newron Pharmaceuticals Evenamide AGM 2026 Xadago®
PRESS RELEASE published on 04/23/2026 at 15:10, 2 months 1 day ago Newron announces AGM 2026 results Newron Pharmaceuticals S.p.A. announces successful AGM 2026 results including new Board members. Focus on developing therapies for nervous system diseases Board Members Newron Pharmaceuticals Thérapies AGM 2026 Nervous System Diseases
BRIEF published on 03/24/2026 at 07:05, 3 months 1 day ago Newron annonce ses résultats pour 2025 et ses perspectives pour 2026. Résultats Financiers Traitement De La Schizophrénie Perspectives Pour 2026 Brevet Accordé Essais Sur L'Evenamide
BRIEF published on 03/24/2026 at 07:05, 3 months 1 day ago Newron Announces 2025 Results and 2026 Outlook Financial Results Schizophrenia Treatment Patent Grant 2026 Outlook Evenamide Trials
PRESS RELEASE published on 03/24/2026 at 07:00, 3 months 1 day ago Newron presents 2025 financial results and provides 2026 outlook Newron Pharmaceuticals S.p.A. presents 2025 financial results and 2026 outlook, including progress on evenamide clinical trials and IP expansion Financial Results Clinical Trials Newron Pharmaceuticals 2026 Outlook IP Expansion
BRIEF published on 03/20/2026 at 07:05, 3 months 5 days ago Newron Pharmaceuticals to Present at SIRS 2026 Newron Pharmaceuticals Evenamide Treatment-resistant Schizophrenia Glutamate Modulation Schizophrenia Research
BRIEF published on 03/20/2026 at 07:05, 3 months 5 days ago Newron Pharmaceuticals présentera ses travaux au SIRS 2026 Newron Pharmaceuticals Evenamide Schizophrénie Résistante Au Traitement Modulation Du Glutamate Recherche Sur La Schizophrénie
PRESS RELEASE published on 03/20/2026 at 07:00, 3 months 5 days ago Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) Newron Pharmaceuticals S.p.A. to present at SIRS 2026 Congress on glutamatergic modulation in treatment-resistant schizophrenia Schizophrenia Newron Pharmaceuticals Congress Glutamatergic Modulation SIRS
BRIEF published on 03/19/2026 at 07:05, 3 months 6 days ago Newron Pharmaceuticals Extends Loan Repayment with EIB European Investment Bank Newron Pharmaceuticals Evenamide Finance Contract ENIGMA-TRS Phase III
Published on 06/25/2026 at 12:00, 27 minutes ago Zomedica's Assisi Loop(R) Products Designated "Fear Free(R)" as Alliance to Advance Low Stress Care and Pet Wellbeing Continues with Fear Free, LLC
Published on 06/25/2026 at 11:30, 57 minutes ago FireFox Gold Closes Second and Final Tranche of Non-Brokered Private Placement
Published on 06/25/2026 at 10:00, 2 hours 27 minutes ago Eagle Plains and Xcite Define Prospective Geophysical Trends at Don Lake and Smitty Uranium Projects, SK
Published on 06/25/2026 at 10:00, 2 hours 27 minutes ago Grande Portage Announces Binding Commercial Offtake Agreement with C$6 Million Equity Financing and US$25 Million Construction Loan, Welcomes Ocean Partners as New Strategic Catalyst for the New Amalga Gold Project
Published on 06/25/2026 at 09:05, 3 hours 22 minutes ago Nano One and Worley Chemetics Complete One-Pot(TM) LFP Cathode Package and Advance to Market
Published on 06/25/2026 at 11:45, 41 minutes ago Five Technology Breakthroughs: Huawei Launches the Next-Generation Grid-Forming ESS Platform LUTERRA®
Published on 06/25/2026 at 11:40, 46 minutes ago Linglong Unveils SPORT MASTER 2 at Tire Cologne 2026
Published on 06/25/2026 at 11:33, 54 minutes ago EQS-Adhoc: Merck KGaA: Merck Agrees to Acquire Bio-Techne Corporation
Published on 06/25/2026 at 11:25, 1 hour 1 minute ago Building AI-Optical Network to Drive New Growth in the AI Era
Published on 06/25/2026 at 11:05, 1 hour 22 minutes ago EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
Published on 06/25/2026 at 07:30, 4 hours 57 minutes ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
Published on 06/25/2026 at 07:30, 4 hours 57 minutes ago Gimv ondertekent een overeenkomst voor de overname van Groupe Cap Vert, de Franse marktleider in multispecialistische essentiële diensten voor het beheer van bomen en groene infrastructuur, van Ambienta.
Published on 06/25/2026 at 07:30, 4 hours 57 minutes ago Gimv signe un accord en vue d’acquérir le Groupe Cap Vert, leader français multi-spécialiste des services de gestion du patrimoine arboré et végétal, auprès d’Ambienta
Published on 06/24/2026 at 19:00, 17 hours 27 minutes ago ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
